What is PRME's current stock price?

PRME (Prime Medicine, Inc.) is currently trading at $2.97 with a market cap of $536.4M.

What sector is Prime Medicine, Inc. in?

Prime Medicine, Inc. (PRME) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is PRME a good stock to buy?

Analysts have a Buy consensus on PRME with a price target of $17.25. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

PRME Prime Medicine, Inc.

Healthcare

$2.97+0.68%ClosedMarket Cap: $536.4M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

6.86

P/S

132.98

EV/EBITDA

-3.00

DCF Value

$-0.06

FCF Yield

-29.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

-1082.7%

Operating Margin

-5121.8%

Net Margin

-4917.6%

ROE

-188.8%

ROA

-67.3%

ROIC

-77.4%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$856.0K	$-49.1M	$—
Q4 null	$838.0K	$-46.1M	$—
FY null	$4.6M	$-201.1M	$—
Q3 null	$1.2M	$-50.6M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$17.25

Target (Median)

$17.00

Target Range

$12.00 - $23.00

1 Strong Buy8 Buy4 Hold0 Sell0 Strong Sell

CitigroupNeutral

2025-11-11

Chardan CapitalBuy

2025-11-10

CitigroupNeutral

2025-08-12

Chardan CapitalBuy

2025-08-08

CitigroupNeutral

2025-05-27

Trading Activity

Insider Trades

View All

Makhni Svetlana Niofficer: Chief Financial Officer

SellFri Apr 17

Makhni Svetlana Niofficer

SellFri Apr 17

Reine Allandirector, officer: Chief Executive Officer

SellFri Feb 27

LEE ANN L.officer: Chief Technical Officer

SellTue Feb 24

Alenson Carmanofficer: See Remarks

SellTue Feb 24

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

2.36

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Peers